TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01289782
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
Study: NCT01289782
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
Study: NCT02093026
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive methotrexate 10-25 mg/week orally or parenterally.
Study: NCT02093026
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive folic acid \>= 5 mg/week or equivalent.
Study: NCT02483533
Drug: LIPO-202
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02483533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01686802
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01255787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vortioxetine placebo-matching tablets
Study: NCT00524849
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zometa 4 mg every four weeks (intravenous)
Study: NCT02029599
Drug: Fang yi qing feng shi granule
Normalized name: qing feng teng stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g, Oral,Three each time, 3 times a day,for 3 months;
Study: NCT02029599
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10g, Oral,Three each time, 3 times a day,for 3 months
Study: NCT02029599
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 7.5-15mg per week，All patients should be used
Study: NCT02029599
Drug: Acetaminophen tablets
Normalized name: Acetaminophen Tablets
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral,0.5g, 1\~2 times a day, when vas=10
Study: NCT02238171
Drug: Atrovent® inhalets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02951845
Drug: JNJ-54416076 (Formulation 1: Direct Compression Tablets)
Normalized name: DIRECT BLUE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive JNJ-54416076 Tablet formulation 1 (5\*5 mg Tablets \[25 mg total\]) under fasted and fed condition in Part 1.
Study: NCT02538003
Drug: LCB01-0371 Tablet 800 mg(R)
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference: taken drug before meal
Study: NCT03101267
Drug: ASP4070
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination at 2-week intervals
Study: NCT02538003
Drug: LCB01-0371 Tablet 800 mg(T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test: taken drug after meal
Study: NCT03101267
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination at 2-week intervals
Study: NCT00911625
Drug: 0.5 units/kg daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
Study: NCT00911625
Drug: 0.25 units/kg daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
Study: NCT00936091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 children received placebo capsules
Study: NCT04744883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In randomized order (crossover) across 2 laboratory sessions each approximately 3 days apart, participants will receive either 1) 2 doses of saline placebo (20ml each) or 2) weight-adjusted doses of Naloxone beginning with a dose of 0.11mg/kg followed by a weight-adjusted dose of 0.055 mg/kg
Study: NCT02937974
Drug: Xuebijing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
Study: NCT02937974
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
Study: NCT04499235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo
Study: NCT00941577
Drug: AIR645
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Study: NCT00941577
Drug: Physiologic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
Study: NCT01190787
Drug: velcade cyclophosphamide prednisone
Normalized name: Velcade
DrugBank: Bortezomib D-mannitol (DB16741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.~Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.~Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days.
Study: NCT04322539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: NCT03239691
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo available as matching capsules for oral administration
Study: NCT02176642
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet taken by mouth daily for 6 weeks
Study: NCT01592227
Drug: Marketed paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed paracetamol
Study: NCT01592227
Drug: Experimental paracetamol formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental paracetamol formulation
Study: NCT03363464
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon-like peptide-1 receptor agonist
Study: NCT02312427
Drug: Suspending DPP-4 inhibitor, in outpatient service
Approvals — FDA: no, EMA: no, PMDA: no
Description: After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
Study: NCT04080076
Drug: Acthar 80 UNT/ML Injectable Solution
Normalized name: Acthar 80 UNT/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACTHar 80 Units SQ 1042 x Week
Study: NCT04132375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The IMP dose to be studied will be 4 mg of protein/kg of subject's weight. Each vial contains 25 mg protein/mL. Therefore, each subject must receive 0.16 mL/kg.~The IMP will be added to the 100 mL infusion bag of saline solution. Doses will be administered as an infusion at 2.0 mL/min over 50 min with an interval of 24 h between doses.
Study: NCT00245583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching tablet
Study: NCT00829283
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One pill daily
Study: NCT00393835
Drug: Azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00665626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, orally, twice-a-day
Study: NCT00825851
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00322153
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo oral administration once daily.
Study: NCT01000961
Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
Normalized name: cysteamine Delayed Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks
Study: NCT03712254
Drug: Fosphenytoin
Normalized name: Fosphenytoin
DrugBank: Fosphenytoin (DB01320)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with trigeminal neuralgia that due to acute exacerbations of trigeminal neuralgia pain are admitted for fosphenytoin loading are the subjects of interest.
Study: NCT03242993
Drug: [18F]-AzaFol
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
Study: NCT03242993
Drug: folarell
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection
Study: NCT03291418
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of gastrointestinal effects
Study: NCT01283373
Drug: DSTP3086S
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSTP3086S administered intravenously
Study: NCT01283373
Drug: DSTP3086S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating intravenous dose
Study: NCT00349271
Drug: Standart therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: All drug with clinical evidence of benefical effect in Chagas disease
Study: NCT03462290
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution without botulinum toxin A, injected towards the sphenopalatine ganglion using MultiGuide
Study: NCT00378079
Drug: Counseling + Transfer
Normalized name: SET,TRANSFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling only in prison, with opportunity to enter methadone maintenance upon release
Study: NCT03905447
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care antifungal medication
Study: NCT00006044
Drug: therapeutic testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03091777
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive arm of the study
Study: NCT02268019
Drug: epinephrine injection
Normalized name: epinephrine Injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04136756
Drug: NKTR-255
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
Study: NCT04136756
Drug: NKTR-255 Q21
Approvals — FDA: no, EMA: no, PMDA: no
Description: NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
Study: NCT01379079
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin intake at bedtime
Study: NCT01379079
Drug: Acetylsalicylic acid lysinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin intake on awakening
Study: NCT02220998
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF/VEL (400/100 mg) FDC tablet administered orally once daily
Study: NCT02220998
Drug: SOF
Normalized name: Kasof
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOF 400 mg tablet administered orally once daily
Study: NCT01336608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00089674
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
Study: NCT02763566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00515385
Drug: MGAWN1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.~Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg
Study: NCT00515385
Drug: MGAWN1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose
Study: NCT01957631
Drug: Corticosteroid injection (Bupivacaine and Depo Medrol)
Normalized name: Depo-Medrol
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
Study: NCT00201734
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
Study: NCT00822263
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-oxidant in a pill format
Study: NCT02063386
Drug: AZD1722
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose 15 mg of \[14C\]AZD1722
Study: NCT01776619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 day repeated BID doses
Study: NCT01571024
Drug: BKM120
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKM120 40 mg, orally, once daily.
Study: NCT01571024
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
Study: NCT00545181
Drug: Vaginal acidifying gel (RepHresh)
Normalized name: Rephresh Pro-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: placement of vaginal acidifying gel into vagina to restore normal vaginal pH.
Study: NCT01159119
Drug: EUR-1066-A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
Study: NCT01159119
Drug: EUR-1066-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
Study: NCT02820714
Drug: BLI801 Laxative
Normalized name: LAXATIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI801 Laxative
Study: NCT03395574
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug will be given after 30 minutes as placebo in control group
Study: NCT00739596
Drug: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
Study: NCT01289431
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered daily to each eye for 2 weeks following allergen challenge using a CAC model
Study: NCT02305277
Drug: BIA 9-1067 (clinical micronized, CM)
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02855632
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
Study: NCT02855632
Drug: hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
Study: NCT02054468
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.1-0.2µg/kg/min)
Study: NCT00805233
Drug: combination ranibizumab + bromfenac
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
Study: NCT02770443
Drug: withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: withdrawal of beta blocker and ACE inhibitors
Study: NCT02770443
Drug: standard of CARE
Approvals — FDA: no, EMA: no, PMDA: no
Description: STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
Study: NCT02718976
Drug: Lidocaine-epinephrine added gadoterate meglumine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
Study: NCT01135108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo IV Infusion
Study: NCT01120223
Drug: LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily application
Study: NCT03216954
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo capsules
Study: NCT00829439
Drug: Levodopa/Carbidopa (4:1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosages are based on levodopa.~Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.~Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day.
Study: NCT00252304
Drug: Zinc (zinc sulphate)
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
Study: NCT00252304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00842088
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule. Administered orally once a day on dosing days.
Study: NCT00842088
Drug: HQK-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
Study: NCT01676363
Drug: Diflunisal
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label diflunisal 500 mg twice daily for 4 weeks
Study: NCT01591850
Drug: RO5093151
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT00298025
Drug: Cetrotide®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is \>=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
Study: NCT00298025
Drug: Antagon ™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is \>=14 mm until r-hCG day.
Study: NCT01322308
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet taken once a day
Study: NCT02374047
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03624530
Drug: Tyrosine kinase inhibitor (TKIs)
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TKI was selected according to the mutation results of ABL kinase region. Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d. Then increase the dosage of TKI gradually and increase to therapeutic dose within one month. The duration of TKI was 180 days.
Study: NCT00967928
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
Study: NCT04048811
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: The induction dose is 0.4mg/mg. The initial maintenance dose of the first 6 subjects is 1 mg/kg/h. For the subsequent enrolled subjects, the investigator could adjust the subsequent initial maintenance dose according to the dose response of the first 6 subjects, so as to explore the optimal initial maintenance dose. The range of the initial maintenance dose is 1 (± 0.5) mg/kg/h, i.e. the minimum initial maintenance dose should not be less than 0.5 mg/kg/h, and the maximum should not be more than 1.5 mg/kg/h.
Study: NCT00352716
Drug: Smecta (Diosmectite), duration of treatment - 7 days
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02934529
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
Study: NCT01444677
Drug: MB12066
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB12066 300mg
Study: NCT01444677
Drug: MB12066
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB12066 400mg
Study: NCT01444677
Drug: MB12066
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB12066 100mg
Study: NCT01444677
Drug: MB12066
Approvals — FDA: no, EMA: no, PMDA: no
Description: MB12066 200mg
Study: NCT01444677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
Study: NCT00812305
Drug: SKY0402 300mg in healthy patients
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
Study: NCT01540682
Drug: MLN8237
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.